miR-22 is a novel mediator of vascular smooth muscle cell phenotypic modulation and neointima formation

Circulation

Volumn 137, Issue 17, 2018, Pages 1824-1841

  Yang, Feng ^a,b   Chen, Qishan ^a   He, Shiping ^b   Yang, Mei ^a   Maguire, Eithne Margaret ^b   An, Weiwei ^b   Afzal, Tayyab Adeel ^b   Luong, Le Anh ^b   Zhang, Li ^a   Xiao, Qingzhong ^b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Cell movement; Cell proliferation; MDS1 and EVI1 complex locus protein; Methyl CpG binding protein 2; MicroRNAs; Neointima

Indexed keywords

AGOMIR 22; HISTONE DEACETYLASE 4; MDS1 AND EVI1 COMPLEX LOCUS PROTEIN; METHYL CPG BINDING PROTEIN 2; MICRORNA; MICRORNA 22; PIFITHRIN ALPHA; PLATELET DERIVED GROWTH FACTOR; SMOOTHELIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSGELIN; UNCLASSIFIED DRUG; ANTAGOMIR; MIRN22 MICRORNA, HUMAN; MIRN22 MICRORNA, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERY INJURY; ARTICLE; CELL COUNTING; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FEMORAL ARTERY; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE SWITCHING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEG AMPUTATION; LUCIFERASE ASSAY; MIDDLE AGED; MOUSE; NEOINTIMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; VASCULAR DISEASE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; WOUND HEALING ASSAY; AGED; ANIMAL; BLOOD VESSEL INJURY; CASE CONTROL STUDY; CELL CULTURE; CELL MOTION; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INJURIES; MALE; METABOLISM; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; TISSUE CULTURE TECHNIQUE; VASCULAR SMOOTH MUSCLE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTAGOMIRS; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FEMORAL ARTERY; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICRORNAS; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PHENOTYPE; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUES; VASCULAR SYSTEM INJURIES;

EID: 85051770266     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.027799     Document Type: Article

References (63)

1. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012;95:156–164. doi: 10.1093/cvr/cvs115.
2. Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13–40. doi: 10.1146/annurev-physi-ol-012110-142315.
3. Albinsson S, Sessa WC. Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury? Physiol Genomics. 2011;43:529–533. doi: 10.1152/physiolgenomics.00146.2010.
4. Condorelli G, Latronico MV, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol. 2014;63:2177–2187. doi: 10.1016/j.jacc.2014.01.050.
5. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest. 2013;123:11–18. doi: 10.1172/JCI62876.
6. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508–522. doi: 10.1161/CIRCRESAHA.111.247445.
7. Chen J, Yin H, Jiang Y, Radhakrishnan SK, Huang ZP, Li J, Shi Z, Kilsdonk EP, Gui Y, Wang DZ, Zheng XL. Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation. Arterioscler Thromb Vasc Biol. 2011;31:368–375. doi: 10.1161/ATVBAHA.110.218149.
8. Xu F, Ahmed AS, Kang X, Hu G, Liu F, Zhang W, Zhou J. MicroRNA-15b/16 attenuates vascular neointima formation by promoting the contractile phenotype of vascular smooth muscle through targeting YAP. Arterioscler Thromb Vasc Biol. 2015;35:2145–2152. doi: 10.1161/AT-VBAHA.115.305748.
9. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007;100:1579–1588. doi: 10.1161/CIRCRESAHA.106.141986.
10. Wang M, Li W, Chang GQ, Ye CS, Ou JS, Li XX, Liu Y, Cheang TY, Huang XL, Wang SM. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol. 2011;31:2044–2053. doi: 10.1161/ATVBAHA.111.229559.
11. Yu X, Zhang L, Wen G, Zhao H, Luong LA, Chen Q, Huang Y, Zhu J, Ye S, Xu Q, Wang W, Xiao Q. Upregulated sirtuin 1 by miRNA-34a is required for smooth muscle cell differentiation from pluripotent stem cells. Cell Death Differ. 2015;22:1170–1180. doi: 10.1038/cdd.2014.206.
12. Chen Q, Yang F, Guo M, Wen G, Zhang C, Luong le A, Zhu J, Xiao Q, Zhang L. miRNA-34a reduces neointima formation through inhibiting smooth muscle cell proliferation and migration. J Mol Cell Cardiol. 2015;89(pt A):75–86. doi: 10.1016/j.yjmcc.2015.10.017.
13. Torella D, Iaconetti C, Catalucci D, Ellison GM, Leone A, Waring CD, Bo-chicchio A, Vicinanza C, Aquila I, Curcio A, Condorelli G, Indolfi C. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res. 2011;109:880–893. doi: 10.1161/CIRCRESAHA.111.240150.
14. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460:705–710. doi: 10.1038/ nature08195.
15. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet. 2011;4:197–205. doi: 10.1161/CIRC-GENETICS.110.958702.
16. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, Richardson JA, Bassel-Duby R, Olson EN. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166–2178. doi: 10.1101/gad.1842409.
17. Boettger T, Beetz N, Kostin S, Schneider J, Krüger M, Hein L, Braun T. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009;119:2634–2647. doi: 10.1172/JCI38864.
18. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105:158–166. doi: 10.1161/CIRCRESAHA.109.197517.
19. Zhao N, Koenig SN, Trask AJ, Lin CH, Hans CP, Garg V, Lilly B. MicroRNA miR145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. Circ Res. 2015;116:23–34. doi: 10.1161/CIRCRE-SAHA.115.303970.
20. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009;16:1590–1598. doi: 10.1038/cdd.2009.153.
21. Sun L, Bai Y, Zhao R, Sun T, Cao R, Wang F, He G, Zhang W, Chen Y, Ye P, Du G. Oncological miR-182-3p, a novel smooth muscle cell phenotype modulator, evidences from model rats and patients. Arterioscler Thromb Vasc Biol. 2016;36:1386–1397. doi: 10.1161/ATVBAHA.115.307412.
22. Afzal TA, Luong LA, Chen D, Zhang C, Yang F, Chen Q, An W, Wilkes E, Yashiro K, Cutillas PR, Zhang L, Xiao Q. nck associated protein 1 modulated by miRNA-214 determines vascular smooth muscle cell migration, proliferation, and neointima hyperplasia. J Am Heart Assoc. 2016;5:e004629.
23. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2009;104:476–487. doi: 10.1161/CIR-CRESAHA.108.185363.
24. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Induction of microR-NA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem. 2009;284:3728–3738. doi: 10.1074/jbc.M808788200.
25. Li P, Liu Y, Yi B, Wang G, You X, Zhao X, Summer R, Qin Y, Sun J. MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1. Cardiovasc Res. 2013;99:185–193. doi: 10.1093/cvr/cvt082.
26. Li P, Zhu N, Yi B, Wang N, Chen M, You X, Zhao X, Solomides CC, Qin Y, Sun J. MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ Res. 2013;113:1117–1127. doi: 10.1161/CIRCRESAHA.113.301306.
27. Ling B, Wang GX, Long G, Qiu JH, Hu ZL. Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 2012;138:1355–1361. doi: 10.1007/s00432-012-1194-2.
28. Zhang G, Xia S, Tian H, Liu Z, Zhou T. Clinical significance of miR-22 expression in patients with colorectal cancer. Med Oncol. 2012;29:3108–3112. doi: 10.1007/s12032-012-0233-9.
29. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol. 2011;193:409–424. doi: 10.1083/jcb.201010100.
30. Gupta SK, Foinquinos A, Thum S, Remke J, Zimmer K, Bauters C, de Groote P, Boon RA, de Windt LJ, Preissl S, Hein L, Batkai S, Pinet F, Thum T. Preclinical development of a microRNA-based therapy for elderly patients with myocardial infarction. J Am Coll Cardiol. 2016;68:1557–1571. doi: 10.1016/j.jacc.2016.07.739.
31. Jazbutyte V, Fiedler J, Kneitz S, Galuppo P, Just A, Holzmann A, Bauersachs J, Thum T. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr). 2013;35:747–762. doi: 10.1007/ s11357-012-9407-9.
32. Gurha P, Abreu-Goodger C, Wang T, Ramirez MO, Drumond AL, van Don-gen S, Chen Y, Bartonicek N, Enright AJ, Lee B, Kelm RJ Jr, Reddy AK, Taffet GE, Bradley A, Wehrens XH, Entman ML, Rodriguez A. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation. 2012;125:2751–2761. doi: 10.1161/ CIRCULATIONAHA.111.044354.
33. Huang ZP, Chen J, Seok HY, Zhang Z, Kataoka M, Hu X, Wang DZ. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res. 2013;112:1234–1243. doi: 10.1161/CIRCRESAHA.112.300682.
34. Zhao H, Wen G, Wen G, Huang Y, Yu X, Chen Q, Afzal TA, Luong le A, Zhu J, Ye S, Shu Y, Zhang L, Xiao Q. MicroRNA-22 regulates smooth muscle cell differentiation from stem cells by targeting methyl CpG-binding protein 2. Arterioscler Thromb Vasc Biol. 2015;35:918–929. doi: 10.1161/ ATVBAHA.114.305212.
35. Xiao Q, Zeng L, Zhang Z, Margariti A, Ali ZA, Channon KM, Xu Q, Hu Y. Sca-1+ progenitors derived from embryonic stem cells differentiate into endothelial cells capable of vascular repair after arterial injury. Arterioscler Thromb Vasc Biol. 2006;26:2244–2251. doi: 10.1161/01. ATV.0000240251.50215.50.
36. Zeng L, Xiao Q, Margariti A, Zhang Z, Zampetaki A, Patel S, Capogrossi MC, Hu Y, Xu Q. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J Cell Biol. 2006;174:1059–1069. doi: 10.1083/jcb.200605113.
37. Xiao Q, Zhang F, Grassia G, Hu Y, Zhang Z, Xing Q, Yin X, Maddaluno M, Drung B, Schmidt B, Maffia P, Ialenti A, Mayr M, Xu Q, Ye S. Matrix metalloproteinase-8 promotes vascular smooth muscle cell proliferation and neointima formation. Arterioscler Thromb Vasc Biol. 2014;34:90–98. doi: 10.1161/ATVBAHA.113.301418.
38. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
39. Zhang L, Chen Q, An W, Yang F, Maguire EM, Chen D, Zhang C, Wen G, Yang M, Dai B, Luong LA, Zhu J, Xu Q, Xiao Q. Novel pathological role of hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1) in vascular smooth muscle cell function and neointima hyperplasia. Arterioscler Thromb Vasc Biol. 2017;37:2182–2194. doi: 10.1161/ATVBA-HA.117.310020.
40. Clarke MC, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res. 2010;106:363–372. doi: 10.1161/CIRCRESAHA.109.208389.
41. Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res. 2008;102:1529–1538. doi: 10.1161/CIRCRESAHA.108.175976.
42. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006;12:1075–1080. doi: 10.1038/nm1459.
43. Usui T, Morita T, Okada M, Yamawaki H. Histone deacetylase 4 controls neointimal hyperplasia via stimulating proliferation and migration of vascular smooth muscle cells. Hypertension. 2014;63:397–403. doi: 10.1161/HYPERTENSIONAHA.113.01843.
44. Liu R, Jin Y, Tang WH, Qin L, Zhang X, Tellides G, Hwa J, Yu J, Martin KA. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation. 2013;128:2047–2057. doi: 10.1161/CIRCULA-TIONAHA.113.002887.
45. Chen HZ, Wang F, Gao P, Pei JF, Liu Y, Xu TT, Tang X, Fu WY, Lu J, Yan YF, Wang XM, Han L, Zhang ZQ, Zhang R, Zou MH, Liu DP. Age-associated sirtuin 1 reduction in vascular smooth muscle links vascular senescence and inflammation to abdominal aortic aneurysm. Circ Res. 2016;119:1076–1088. doi: 10.1161/CIRCRESAHA.116.308895.
46. Jentzsch C, Leierseder S, Loyer X, Flohrschütz I, Sassi Y, Hartmann D, Thum T, Laggerbauer B, Engelhardt S. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol. 2012;52:13–20. doi: 10.1016/j.yjmcc.2011.07.010.
47. Gurha P, Wang T, Larimore AH, Sassi Y, Abreu-Goodger C, Ramirez MO, Reddy AK, Engelhardt S, Taffet GE, Wehrens XH, Entman ML, Rodriguez A. microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription. PLoS One. 2013;8:e75882. doi: 10.1371/journal.pone.0075882.
48. Millette E, Rauch BH, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells. Trends Cardiovasc Med. 2006;16:25–28. doi: 10.1016/j.tcm.2005.11.003.
49. Li Y, Huang J, Jiang Z, Zhong Y, Xia M, Wang H, Jiao Y. MicroRNA-145 regulates platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration by targeting CD40. Am J Transl Res. 2016;8:1813–1825.
50. Kim S, Kang H. miR-15b induced by platelet-derived growth factor signaling is required for vascular smooth muscle cell proliferation. BMB Rep. 2013;46:550–554.
51. Su A, He S, Tian B, Hu W, Zhang Z. MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS One. 2013;8:e71309. doi: 10.1371/journal.pone.0071309.
52. Elston R, Inman GJ. Crosstalk between p53 and TGF-β Signalling. J Signal Transduct. 2012;2012:294097. doi: 10.1155/2012/294097.
53. Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkon R, Agami R. p53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biol. 2013;14:R32. doi: 10.1186/gb-2013-14-4-r32.
54. Hinai AA, Valk PJ. Review: Aberrant EVI1 expression in acute myeloid leu-kaemia. Br J Haematol. 2016;172:870–878. doi: 10.1111/bjh.13898.
55. Yuan X, Wang X, Bi K, Jiang G. The role of EVI-1 in normal hematopoiesis and myeloid malignancies (review). Int J Oncol. 2015;47:2028–2036. doi: 10.3892/ijo.2015.3207.
56. Yoshimi A, Kurokawa M. Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget. 2011;2:575–586. doi: 10.18632/oncotarget.304.
57. Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene. 2007;396:346–357. doi: 10.1016/j.gene.2007.04.012.
58. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, Meyer S, Erpelinck-Verschueren C, Greally J, Löwenberg B, Melnick A, Del-wel R. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2011;117:234–241. doi: 10.1182/ blood-2010-04-281337.
59. Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res. 2006;66:11360–11369. doi: 10.1158/0008-5472.CAN-06-1774.
60. Shen L, Gong F, Tian W, Li W, Zhang F, Qian J, Sun A, Zou Y, Yang W, Ge J. Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model. Biomed Res Int. 2013;2013:937936. doi: 10.1155/2013/937936.
61. Yang W, Ge J, Liu H, Zhao K, Liu X, Qu X, Li W, Huang Y, Sun A, Zou Y. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model. Cardiovasc Res. 2006;72:483–493. doi: 10.1016/j. cardiores.2006.08.010.
62. Shen L, Yang W, Yin JS, Liu XB, Wu YZ, Sun AJ, Qian JY, Ge JB. Nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease. Chin Med J (Engl). 2015;128:768–773. doi: 10.4103/0366-6999.152490.
63. Zhang S, Zhang Y, Li S, Li Z. Efficacy of arsenic trioxide drug-eluting stents in the treatment of coronary heart disease. Exp Ther Med. 2017;13:1634–1636. doi: 10.3892/etm.2017.4106.